SG11202002089RA - Constrained conditionally activated binding proteins - Google Patents
Constrained conditionally activated binding proteinsInfo
- Publication number
- SG11202002089RA SG11202002089RA SG11202002089RA SG11202002089RA SG11202002089RA SG 11202002089R A SG11202002089R A SG 11202002089RA SG 11202002089R A SG11202002089R A SG 11202002089RA SG 11202002089R A SG11202002089R A SG 11202002089RA SG 11202002089R A SG11202002089R A SG 11202002089RA
- Authority
- SG
- Singapore
- Prior art keywords
- constrained
- binding proteins
- activated binding
- conditionally activated
- conditionally
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762555943P | 2017-09-08 | 2017-09-08 | |
US201762586627P | 2017-11-15 | 2017-11-15 | |
US201762587318P | 2017-11-16 | 2017-11-16 | |
PCT/US2018/049774 WO2019051102A2 (en) | 2017-09-08 | 2018-09-06 | Constrained conditionally activated binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002089RA true SG11202002089RA (en) | 2020-04-29 |
Family
ID=63788010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002089RA SG11202002089RA (en) | 2017-09-08 | 2018-09-06 | Constrained conditionally activated binding proteins |
Country Status (18)
Country | Link |
---|---|
US (5) | US11406710B2 (en) |
EP (1) | EP3679067A2 (en) |
JP (2) | JP7268005B2 (en) |
KR (1) | KR20200047687A (en) |
CN (1) | CN111356700A (en) |
AU (3) | AU2018328291B2 (en) |
BR (1) | BR112020004543A2 (en) |
CA (1) | CA3075034A1 (en) |
CL (3) | CL2020000570A1 (en) |
EC (1) | ECSP20021323A (en) |
IL (3) | IL302613A (en) |
MX (1) | MX2020002667A (en) |
PE (1) | PE20212205A1 (en) |
PH (1) | PH12020500474A1 (en) |
SG (1) | SG11202002089RA (en) |
TW (2) | TWI823811B (en) |
WO (1) | WO2019051102A2 (en) |
ZA (1) | ZA202002325B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
CN112654633A (en) | 2018-06-22 | 2021-04-13 | 科优基因公司 | Cytokine-based bioactivatable agents and methods of use thereof |
US20210309756A1 (en) | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
EP3934762A1 (en) * | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
EP3934761A1 (en) * | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
MX2021013766A (en) * | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof. |
CN114945597A (en) * | 2020-01-17 | 2022-08-26 | 艾提欧生物疗法有限公司 | Pre-antibodies to reduce off-target toxicity |
JP7483896B2 (en) * | 2020-01-17 | 2024-05-15 | エショー バイオセラピー, インク. | Pro-Antibodies Reduce Off-Target Toxicity |
CA3185968A1 (en) * | 2020-07-13 | 2022-01-20 | Tony Lahoutte | Antibody fragment against folr1 |
TW202214707A (en) | 2020-08-17 | 2022-04-16 | 美商馬弗瑞克療法公司 | Constrained conditionally activated binding proteins |
WO2022051647A2 (en) * | 2020-09-04 | 2022-03-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding protein constructs with human serum albumin domains |
EP4259193A1 (en) | 2020-12-09 | 2023-10-18 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
AU2021402183A1 (en) | 2020-12-14 | 2023-07-06 | Takeda Pharmaceutical Company Limited | Conditionally bispecific binding proteins |
WO2022212668A1 (en) * | 2021-03-31 | 2022-10-06 | Heat Biologics, Inc. | Methods and compositions related to tnfrsf25/dr3 agonists |
WO2022214978A1 (en) * | 2021-04-06 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Therapeutic methods using constrained conditionally activated binding proteins |
WO2023164551A1 (en) * | 2022-02-23 | 2023-08-31 | Takeda Pharmaceutical Company Limited | Conditionally bispecific binding proteins |
WO2023212662A2 (en) * | 2022-04-28 | 2023-11-02 | Oregon Health & Science University | Compositions and methods for modulating antigen binding activity |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
EP0905253A3 (en) | 1992-12-03 | 2000-11-02 | Genzyme Corporation | Adenoviral vector deleted of all E4-ORF except ORF6 |
DE69434594T2 (en) | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US20020076406A1 (en) | 2000-07-25 | 2002-06-20 | Leung Shui-On | Multivalent target binding protein |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
DE10231109A1 (en) | 2002-07-10 | 2004-01-22 | Daimlerchrysler Ag | exhaust turbine |
US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
US20100003253A1 (en) | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
KR20120125634A (en) | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | Multispecific deimmunized cd3-binders |
JP2009511032A (en) | 2005-10-11 | 2009-03-19 | アブリンクス エン.ヴェー. | Nanobodies and polypeptides for EGFR and IGF-IR |
US20090252681A1 (en) | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
KR20080090441A (en) | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Epha2 bite molecules and uses thereof |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
NZ580755A (en) | 2007-04-03 | 2012-05-25 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
CA2696263C (en) * | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
CN102482347B (en) * | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | Modified antibody compositions, and methods of making and using thereof |
UY32603A (en) | 2009-05-01 | 2010-12-31 | Abbott Lab | IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US20110029476A1 (en) | 2009-07-29 | 2011-02-03 | Kas Kasravi | Indicating relationships among text documents including a patent based on characteristics of the text documents |
SG179027A1 (en) * | 2009-09-18 | 2012-04-27 | Micromet Ag | Dosage regimen for administering an epcamxcd3 bispecific antibody |
RU2012149227A (en) * | 2010-05-20 | 2014-06-27 | Аблинкс Нв | BIOLOGICAL MATERIALS RELATING TO HER3 |
US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
WO2012025525A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
EP2714733B1 (en) | 2011-05-21 | 2019-01-23 | MacroGenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
JP2014522641A (en) | 2011-07-01 | 2014-09-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Relaxin fusion polypeptides and uses thereof |
EP2987806A3 (en) | 2011-08-17 | 2016-07-13 | Glaxo Group Limited | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies |
UY34504A (en) * | 2011-12-09 | 2013-06-28 | Amgen Res Munich Gmbh | Prevention of adverse effects caused by bispecific antibodies EpCAMxCD3 |
EP3907241A1 (en) | 2012-01-13 | 2021-11-10 | Julius-Maximilians-Universität Würzburg | Dual antigen-induced bipartite functional complementation |
AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
MX353382B (en) | 2012-03-01 | 2018-01-10 | Amgen Res Munich Gmbh | Long life polypeptide binding molecules. |
SG11201406943XA (en) | 2012-04-27 | 2014-12-30 | Cytomx Therapeutics Inc | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
IN2014MN02635A (en) | 2012-06-22 | 2015-10-16 | Cytomx Therapeutics Inc | |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
BR112015026143A2 (en) | 2013-04-19 | 2017-10-17 | Covagen Ag | Bispecific and nucleic acid ligand molecules, vector, host cell or non-human host, and pharmaceutical composition |
US9517276B2 (en) | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
ES2897579T3 (en) | 2013-06-10 | 2022-03-01 | Dana Farber Cancer Inst Inc | Methods and compositions for reducing immunosuppression by tumor cells |
CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
UA119167C2 (en) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Bispecific antibodies that bind to cd38 and cd3 |
EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
AU2015294834B2 (en) | 2014-07-31 | 2021-04-29 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
JP6925264B2 (en) | 2014-08-27 | 2021-08-25 | メモリアル スローン ケタリング キャンサー センター | Antibodies, compositions and uses |
US20170260261A1 (en) | 2014-08-28 | 2017-09-14 | Bioatla, Llc | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells |
WO2016046778A2 (en) * | 2014-09-25 | 2016-03-31 | Amgen Inc | Protease-activatable bispecific proteins |
EP3277316A1 (en) * | 2015-04-02 | 2018-02-07 | Ablynx N.V. | Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity |
EP3288981A1 (en) | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
SG10201913767VA (en) * | 2015-05-04 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
ES2754427T3 (en) * | 2015-05-13 | 2020-04-17 | Ablynx Nv | T cell recruitment polypeptides based on TCR alpha / beta reactivity |
MX2017014908A (en) | 2015-05-21 | 2018-08-15 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use. |
JP2018523686A (en) * | 2015-08-17 | 2018-08-23 | マクロジェニクス,インコーポレーテッド | Bispecific monovalent diabody capable of binding to B7-H3 and CD3 and uses thereof |
US11161641B2 (en) | 2015-11-16 | 2021-11-02 | Fuji Seal International, Inc. | Method and system for forming sleeved containers |
ES2873846T3 (en) | 2015-11-19 | 2021-11-04 | Revitope Ltd | Functional Antibody Fragment Complementation for a Two-Component System for Targeted Elimination of Unwanted Cells |
JP7195927B2 (en) | 2016-03-08 | 2022-12-26 | 武田薬品工業株式会社 | Inducible binding proteins and methods of use thereof |
KR102530742B1 (en) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | single domain serum albumin binding protein |
SG11201810331YA (en) | 2016-05-20 | 2018-12-28 | Harpoon Therapeutics Inc | Single chain variable fragment cd3 binding proteins |
CN106632681B (en) | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | Anti- EGFR and AntiCD3 McAb bispecific antibody and its application |
WO2018071777A1 (en) | 2016-10-14 | 2018-04-19 | Harpoon Therapeutics, Inc. | Innate immune cell trispecific binding proteins and methods of use |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2018160671A1 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
KR20200005732A (en) | 2017-04-11 | 2020-01-16 | 인히브릭스, 인크. | Multispecific Polypeptide Constructs with Limited CD3 Binding and Methods Using the Same |
JP2020534811A (en) | 2017-09-08 | 2020-12-03 | マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. | Conditionally activated binding moiety containing the Fc region |
AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
EP3794044A4 (en) | 2018-05-14 | 2022-02-16 | Harpoon Therapeutics, Inc. | Dual binding moiety |
EP3794038A4 (en) | 2018-05-14 | 2022-02-16 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
US20210269530A1 (en) | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
CN113286811A (en) | 2018-07-30 | 2021-08-20 | 南加利福尼亚大学 | Improving the efficacy and safety of adoptive cell therapy |
US20210309756A1 (en) | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
KR20210105890A (en) | 2018-12-17 | 2021-08-27 | 레비토프 리미티드 | Twin Immune Cell Engager |
EP3897719A4 (en) | 2018-12-21 | 2022-11-02 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Protease cleavable bispecific antibodies and uses thereof |
EP3934761A1 (en) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
EP3934762A1 (en) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
US20220323600A1 (en) | 2019-05-02 | 2022-10-13 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
-
2018
- 2018-09-06 AU AU2018328291A patent/AU2018328291B2/en active Active
- 2018-09-06 CA CA3075034A patent/CA3075034A1/en active Pending
- 2018-09-06 WO PCT/US2018/049774 patent/WO2019051102A2/en unknown
- 2018-09-06 PE PE2020000334A patent/PE20212205A1/en unknown
- 2018-09-06 JP JP2020513686A patent/JP7268005B2/en active Active
- 2018-09-06 SG SG11202002089RA patent/SG11202002089RA/en unknown
- 2018-09-06 MX MX2020002667A patent/MX2020002667A/en unknown
- 2018-09-06 KR KR1020207010104A patent/KR20200047687A/en not_active Application Discontinuation
- 2018-09-06 IL IL302613A patent/IL302613A/en unknown
- 2018-09-06 BR BR112020004543-8A patent/BR112020004543A2/en unknown
- 2018-09-06 CN CN201880072182.XA patent/CN111356700A/en active Pending
- 2018-09-06 IL IL302614A patent/IL302614A/en unknown
- 2018-09-06 IL IL273119A patent/IL273119B2/en unknown
- 2018-09-06 EP EP18782832.2A patent/EP3679067A2/en active Pending
- 2018-09-07 US US16/124,556 patent/US11406710B2/en active Active
- 2018-09-07 TW TW112115037A patent/TWI823811B/en active
- 2018-09-07 TW TW107131542A patent/TWI812637B/en active
-
2020
- 2020-03-06 CL CL2020000570A patent/CL2020000570A1/en unknown
- 2020-03-09 PH PH12020500474A patent/PH12020500474A1/en unknown
- 2020-04-07 EC ECSENADI202021323A patent/ECSP20021323A/en unknown
- 2020-05-04 ZA ZA2020/02325A patent/ZA202002325B/en unknown
-
2021
- 2021-08-25 CL CL2021002241A patent/CL2021002241A1/en unknown
- 2021-08-25 CL CL2021002242A patent/CL2021002242A1/en unknown
-
2022
- 2022-05-13 US US17/743,995 patent/US11744893B2/en active Active
- 2022-05-13 US US17/743,961 patent/US11744892B2/en active Active
-
2023
- 2023-01-27 AU AU2023200434A patent/AU2023200434A1/en active Pending
- 2023-01-27 AU AU2023200437A patent/AU2023200437A1/en active Pending
- 2023-04-20 JP JP2023069230A patent/JP7490853B2/en active Active
- 2023-07-21 US US18/356,985 patent/US20240139317A1/en active Pending
- 2023-07-21 US US18/357,013 patent/US20230414752A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273119A (en) | Constrained conditionally activated binding proteins | |
IL272643A (en) | Binding agents | |
IL273199A (en) | Gpcr binding proteins and synthesis thereof | |
ZA201808160B (en) | Bispecific binding proteins and uses thereof | |
SG10202107880XA (en) | Mesothelin binding proteins | |
IL272064A (en) | Binding proteins 1 | |
ZA201804317B (en) | Altered april binding antibodies | |
IL274926A (en) | Engineered dna binding proteins | |
HK1253533A1 (en) | Cd131 binding proteins and uses thereof | |
GB201702091D0 (en) | Specific binding molecules | |
IL268288A (en) | Binding agents | |
GB201711481D0 (en) | Protein purification | |
SG11202001420VA (en) | Modular binding proteins | |
ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
ZA202003722B (en) | Modified globin proteins | |
ZA201901862B (en) | Modified factor h binding protein | |
IL269477A (en) | Il-1r-i binding polypeptide | |
ZA201905544B (en) | Modified haemoglobin proteins | |
GB201703049D0 (en) | Single-strand binding protein | |
GB201615588D0 (en) | TSLP Binding Proteins | |
GB201614627D0 (en) | Antigen binding proteins | |
IL266419A (en) | Binding peptides | |
GB201714038D0 (en) | Modular binding proteins | |
GB201713316D0 (en) | Modular binding proteins | |
GB201702069D0 (en) | Binding polypeptides |